Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SCP-CBN
- Development stage
- Preclinical
- Lead developer
- Nexus Alliance Biopharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral, Topical
01
Overview
SCP-CBN is a preclinical-stage small molecule drug candidate being developed by Nexus Alliance Biopharmaceuticals for the management of carcinogenic pain (cancer-related pain). The product utilizes the company's proprietary Self-Crystalizing Polymer (SCP) technology to deliver cannabinol (CBN), a non-psychoactive cannabinoid found in the *Cannabis sativa* plant. The SCP platform is designed to enhance the solubility, stability, and bioavailability of cannabinoids, which are typically lipophilic and difficult to formulate. Pharmacologically, cannabinol acts as a partial agonist at both the Cannabinoid Receptor 1 (CB1) and Cannabinoid Receptor 2 (CB2). By modulating these receptors within the endocannabinoid system, SCP-CBN aims to alleviate pain and potentially reduce the reliance on opioid analgesics in cancer patients.
- Brand names
- TruCBN
- Other names
- cannabinolCBN
02
Targets
CNR1 (Cannabinoid receptor 1)TRPA1 (Transient receptor potential cation channel subfamily A member 1)TRPV1 (Transient receptor potential cation channel subfamily V member 1)TRPV2 (Transient receptor potential cation channel subfamily V member 2)TRPV3 (Transient receptor potential vanilloid subtype 3)TRPV4 (Transient receptor potential cation channel subfamily V member 4)
Beyond the preview
Go deeper on SCP-CBN.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCP-CBN.